Latest From Cytokinetics Inc.
Key events that could move innovative product candidates nearer the market in the third quarter of 2019 are highlighted in a new Biomedtracker/Meddevicetracker report.
While nearly all former FDA commissioners have served on the board of a pharmaceutical company, a Pink Sheet analysis finds that many have also served on the board of non-profit institutions after leaving public service.
Scrip spoke with Levy, senior vice president of global development, about the company's novel candidates for cardiovascular and inflammatory diseases and cancer, including modalities outside of its primary focus on biologics and small molecules.
The Astellas-partnered drug did not reach statistical significance on any FORTITUDE-ALS endpoints, but clinically significant results over time justify a longer Phase III study that's likely to enroll ALS patients with a faster rate of disease progression.
- Therapeutic Areas
- Musculoskeletal & Connective Tissue Disorders
- North America
- Parent & Subsidiaries
- Cytokinetics Inc.
- Senior Management
Robert I Blum, Pres. & CEO
Sharon Barbari, EVP, Fin. & CFO
Andrew A Wolff, MD, SVP, CMO
Elisabeth A Schnieders, PhD, SVP, Bus. Dev.
Scott R Jordan, VP, Commercial Dev.
- Contact Info
Phone: (650) 624-3000
280 East Grand Ave.
S. San Francisco, CA 94080
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.